You really have no idea what you're talking about. Interim data is ONLY available to an independent data safety monitoring board. Not to the company or researchers. Anything to the contrary would void the study for FDA consideration.
Stop embarrassing yourself.
Let's take a look at what the 2 presentations will actually be.
A1775 - ORBIT-3 and ORBIT-4: Design of a Phase 3 Program to Investigate Safety and Efficacy of Pulmaquin® in Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized with Pseudomonas Aeruginosa (PA) by A. E. O'Donnell, D. Serisier, A. Wanner, J. Froehlich, P. Bruinenberg and I. Gonda
A3734 - Liposome-Ciprofloxacin Inhibits Mycobacterium avium subs hominissuis (MAH) Microaggregate Formation in a Dose and Time Dependent Manner, by L. E. Bermudez, J. Blanchard, L. Babrak, and I. Gonda
First one is a talk about the design of the P3 studies. No data.
Second one is data from a study at Oregon State in mice:
Scientists from the Oregon State University, Corvallis (OSU) and Aradigm Corporation (Nasdaq: ARDM) (the “Company”) demonstrated that Aradigm’s investigational drugs Lipoquin and Pulmaquin significantly reduced the growth of the pulmonary non-tuberculous mycobacteria infection (PNTM) after 3 weeks of once daily respiratory tract dosing in mice. The number of colony forming units of Mycobacterium Avium Subsp Hominissuis was reduced by 79% and 77% by Lipoquin and Pulmaquin, respectively (p
You really are the idiot if you think data from a double-blind P3 trial can be used in a presentation before it is unblinded. Any data leakage would void the entire effort.